ContraFect Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CFRXQ research report →
Price Chart
About the company
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections.
- CEO
- Roger J. Pomerantz
- IPO
- 2014
- Employees
- 23
- HQ
- Yonkers, NY, US
Get TickerSpark's AI analysis on CFRXQ
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $107
- P/E
- -0.00
- PEG
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- 0.09
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -347.26%
- ROIC
- -4817.02%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-154,000-4.1%
- Op Income
- $-56,889,000
- Net Income
- $-65,153,000-221.2%
- EPS
- $-124.97-183.3%
- OCF Growth
- -11.8%
- FCF Growth
- -11.9%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -9.57
- RSI (14)
- 48
- Avg Volume
- 692
No earnings-call transcripts are available for CFRXQ yet.
- Free Float
- 100.0%
- Shares Outstanding
- 10.70M
- Float Shares
- 10.70M
Our CFRXQ coverage
Recent articles, reports, and earnings notes.
No research on CFRXQ yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CFRXQ report →